Dana Investment Advisors Inc. Boosts Stake in Axsome Therapeutics, Inc. $AXSM

Dana Investment Advisors Inc. raised its stake in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) by 39.6% during the 3rd quarter, Holdings Channel reports. The fund owned 33,612 shares of the company’s stock after purchasing an additional 9,539 shares during the period. Dana Investment Advisors Inc.’s holdings in Axsome Therapeutics were worth $4,082,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in the stock. Clearstead Advisors LLC lifted its stake in shares of Axsome Therapeutics by 11.4% during the 3rd quarter. Clearstead Advisors LLC now owns 1,328 shares of the company’s stock worth $161,000 after purchasing an additional 136 shares during the last quarter. OneDigital Investment Advisors LLC raised its holdings in Axsome Therapeutics by 5.3% in the third quarter. OneDigital Investment Advisors LLC now owns 9,805 shares of the company’s stock worth $1,191,000 after purchasing an additional 496 shares in the last quarter. Intrust Bank NA lifted its position in shares of Axsome Therapeutics by 30.9% during the third quarter. Intrust Bank NA now owns 3,764 shares of the company’s stock valued at $457,000 after buying an additional 889 shares during the last quarter. Citigroup Inc. lifted its position in shares of Axsome Therapeutics by 67.1% during the third quarter. Citigroup Inc. now owns 142,013 shares of the company’s stock valued at $17,247,000 after buying an additional 57,002 shares during the last quarter. Finally, Lion Street Advisors LLC boosted its holdings in shares of Axsome Therapeutics by 62.0% in the 3rd quarter. Lion Street Advisors LLC now owns 14,677 shares of the company’s stock valued at $1,783,000 after buying an additional 5,619 shares in the last quarter. 81.49% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research firms recently commented on AXSM. TD Cowen reiterated a “buy” rating on shares of Axsome Therapeutics in a research note on Monday. Piper Sandler lifted their price target on shares of Axsome Therapeutics from $148.00 to $223.00 and gave the stock an “overweight” rating in a report on Friday, January 16th. Truist Financial set a $200.00 price objective on Axsome Therapeutics in a report on Monday. Wells Fargo & Company raised their price objective on Axsome Therapeutics from $193.00 to $202.00 and gave the stock an “overweight” rating in a research report on Tuesday. Finally, HC Wainwright upped their target price on Axsome Therapeutics from $200.00 to $260.00 and gave the company a “buy” rating in a research report on Tuesday, January 20th. Seventeen research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $216.12.

Insider Transactions at Axsome Therapeutics

In other news, insider Ari Maizel sold 7,500 shares of the firm’s stock in a transaction dated Wednesday, January 21st. The stock was sold at an average price of $184.44, for a total value of $1,383,300.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Nick Pizzie sold 12,000 shares of Axsome Therapeutics stock in a transaction dated Thursday, January 22nd. The stock was sold at an average price of $187.92, for a total value of $2,255,040.00. Following the sale, the chief financial officer directly owned 42,588 shares of the company’s stock, valued at $8,003,136.96. This trade represents a 21.98% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 308,874 shares of company stock valued at $51,390,805 over the last three months. Company insiders own 22.40% of the company’s stock.

Trending Headlines about Axsome Therapeutics

Here are the key news stories impacting Axsome Therapeutics this week:

• Positive Sentiment: Revenue and commercial strength — Q4 sales jumped roughly 65% year‑over‑year and full‑year 2025 revenue rose strongly, led by Auvelity and Sunosi, beating consensus revenue estimates and showing solid commercial traction. AXSM Q4 Loss Wider Than Expected, Revenues Surge Y/Y on Auvelity Sales
• Positive Sentiment: Pipeline progress — Axsome dosed the first patient in the CLARITY Phase 3 trial of solriamfetol for MDD with excessive daytime sleepiness, adding a near‑term clinical catalyst. Axsome Therapeutics Initiates CLARITY Phase 3 Trial
• Positive Sentiment: Analyst support — Needham reaffirmed a Buy and set a $225 price target, signaling continued bull case and upside potential. Benzinga coverage of Needham rating
• Neutral Sentiment: Earnings materials and call — Management released the Q4 / FY2025 results, slide deck and earnings call transcript; these provide detail behind the revenue beat and guidance/comments for investors to review. Axsome press release / slide deck
• Neutral Sentiment: Mixed EPS reporting — several outlets summarized Q4 results and call highlights (transcript and summaries available), useful for investors but containing varying EPS figures across reports. AXSM Q4 2025 Earnings Call Highlights
• Negative Sentiment: Profitability and accounting headlines — despite revenue strength, Axsome remains loss‑making (negative net margins and a large negative ROE); some reports flagged a wider per‑share loss in certain metrics, creating near‑term investor concern. Axsome Reports Q4 Loss, Tops Revenue Estimates
• Negative Sentiment: Valuation and pipeline skepticism — some analysts and commentators argue the pipeline may be overvalued and commercial uptake risks remain, tempering enthusiasm despite upside price targets. Axsome: Q4 Earnings Review — Pipeline May Be Overvalued

Axsome Therapeutics Trading Down 2.8%

NASDAQ:AXSM opened at $169.95 on Wednesday. The company has a market capitalization of $8.57 billion, a P/E ratio of -46.06, a PEG ratio of 12.57 and a beta of 0.40. The company has a current ratio of 1.57, a quick ratio of 1.50 and a debt-to-equity ratio of 1.66. Axsome Therapeutics, Inc. has a 12 month low of $86.99 and a 12 month high of $191.50. The firm has a fifty day simple moving average of $174.91 and a 200-day simple moving average of $145.40.

Axsome Therapeutics (NASDAQ:AXSM) last released its earnings results on Monday, February 23rd. The company reported ($0.56) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.70) by $0.14. Axsome Therapeutics had a negative return on equity of 251.47% and a negative net margin of 28.69%.The firm had revenue of $196.00 million for the quarter, compared to the consensus estimate of $191.33 million. The firm’s revenue was up 65.0% on a year-over-year basis. On average, equities research analysts anticipate that Axsome Therapeutics, Inc. will post -2.79 earnings per share for the current year.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.